US2005169913A1PendingUtilityA1
Compositions comprising antibodies to human FgI2
Est. expiryMay 15, 2017(expired)· nominal 20-yr term from priority
A61P 43/00A61P 37/06A61P 31/04A61P 35/00A61P 31/12A61P 7/02A61K 2039/505C07K 2319/00G01N 2800/224C12Q 1/37A61K 38/00C07K 2317/70G01N 33/86A61K 48/00A61P 1/00A61P 15/06G01N 33/6893C12N 2799/026A61P 13/12G01N 2800/245G01N 2800/24C07K 16/40C12N 9/647G01N 33/575
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.
Claims
exact text as granted — not AI-modified1 . A composition for use in inhibiting fetal loss in an animal comprising a monoclonal antibody that binds to a human Fgl2 having the amino acid sequence as shown in SEQ.ID.NO:2 and a suitable diluent or carrier.
2 . The composition according to claim 1 wherein the antibody binds an epitope of human Fgl2 having the amino acids sequence DRYPSGNCGLYYSSG (SEQ.ID.NO:18).
3 . A composition for use in inhibiting intestinal transplants and xenogeneic hyperacute liver failure in an animal comprising a monoclonal antibody that binds to a human Fgl2 having the amino acid sequence as shown in SEQ.ID.NO:2 and a suitable diluent or carrier.
4 . The composition according to claim 3 wherein the antibody binds an epitope of human Fgl2 having the amino acid sequence DRYPSGNCGLYYSSG (SEQ.ID.NO:18).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.